Product Description
Cefdinir is used to treat certain infections caused by bacteria such as bronchitis (infection of the airway tubes leading to the lungs); pneumonia; and infections of the skin, ears, sinuses, throat, and tonsils.. Cefdinir is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a698001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Chile | Colombia | Ecuador | Egypt | India | Indonesia | Ireland | Jordan | Korea | Lebanon | Mexico | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Sweden | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: Eastern America
Company Founding Year: 1888
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Abscess|Anthrax|Blepharitis|Bronchitis, Chronic|Carbuncle|Cellulitis|Cystitis|Erysipelas|Escherichia coli Infections|Folliculitis|Haemophilus Infections|Hidradenitis|Influenza, Human|Klebsiella Infections|Lymphadenitis|Lymphangitis|Mastitis|Otitis Media|Otitis Media, Suppurative|Paronychia|Pharyngitis|Pneumonia|Proteus Infections|Pyelonephritis|Pyoderma|Sinusitis|Surgical Wound Infection|Tonsillitis|Urethritis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20130963 |
CTR20130963 | P1 |
Active, not recruiting |
Pyoderma|Pharyngitis|Sinusitis|Paronychia|Influenza, Human|Mastitis|Erysipelas|Cellulitis|Proteus Infections|Anthrax|Blepharitis|Carbuncle|Tonsillitis|Abscess|Cystitis|Otitis Media, Suppurative|Urethritis|Pyelonephritis|Folliculitis|Bronchitis, Chronic|Lymphangitis|Klebsiella Infections|Pneumonia|Escherichia coli Infections|Hidradenitis |
None |
2025-04-29 |
Treatments |
|
CTR20130418 |
CTR20130418 | P1 |
Active, not recruiting |
Klebsiella Infections|Haemophilus Infections|Proteus Infections|Influenza, Human|Escherichia coli Infections |
None |
2025-04-29 |
Treatments |
|
CTR20132519 |
CTR20132519 | P1 |
Recruiting |
Escherichia coli Infections|Pneumonia|Influenza, Human|Erysipelas|Paronychia|Mastitis|Pharyngitis|Abscess|Klebsiella Infections|Cellulitis|Sinusitis|Cystitis|Pyoderma|Haemophilus Infections|Bronchitis, Chronic|Blepharitis|Urethritis|Carbuncle|Lymphadenitis|Surgical Wound Infection|Otitis Media|Pyelonephritis|Proteus Infections|Tonsillitis|Folliculitis |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/26/2023 |
News Article |
Cefdinir Market Size, Share, Growth 2023-2030 |
|
09/14/2023 |
News Article |
Omnicef Market Size, Share, Growth 2023-2030 |
|
09/07/2023 |
News Article |
Cefdinir Market Economic Impacts Expected to Extend to Broader by 2030 |
|
09/04/2023 |
News Article |
Mobile Device Management Market Size 2023 Booming Worldwide by 2031 |